CAP and ASCO Release Updated Guideline on HER2 Testing in Breast Cancer

Leading Healthcare Organizations Recommend to Test All Patients with Invasive Breast Cancer for HER2 StatusNORTHFIELD, ILL.— The College of American Pathologists (CAP) and the American Society of Clinical Oncology (ASCO) today issued a joint, updated guideline aimed at improving the accuracy and reporting of human epidermal growth factor receptor 2 (HER2) testing in patients with invasive breast cancer. The guideline update is based on a systematic review of medical research literature, providing oncologists and pathologists with detailed recommendations for how to test for HER2